Xenetic Biosciences’ (XBIO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research note published on Thursday morning,Benzinga reports.

Xenetic Biosciences Stock Down 3.4 %

NASDAQ:XBIO opened at $3.40 on Thursday. The company has a market cap of $5.24 million, a P/E ratio of -1.28 and a beta of 2.17. The firm’s 50 day moving average is $3.99 and its two-hundred day moving average is $4.00. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48). The firm had revenue of $0.65 million during the quarter, compared to analysts’ expectations of $0.18 million. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. Research analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation bought a new stake in Xenetic Biosciences Inc (NASDAQ:XBIO) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences as of its most recent filing with the Securities & Exchange Commission. 15.12% of the stock is currently owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.